Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions? Sometimes, but clinical judgement is more important than predefined criteria Andrea Apolo, M.D. Shilpa Gupta joaquim bellmunt Jonathan Rosenberg MD Michiel van der Heijden & Lisa Cordes gbr01.safelinks.protection.outlook.com/?url=https%3A%…

Dose-escalation of lutetium PSMA: Final results from a phase I/II trial. Scott Tagawa Weill Cornell Medicine and Zach Klaassen Georgia Cancer Center discuss the safety and efficacy of increasing radioactive doses in a fractionated, dose-dense regimen. #WatchNow > bit.ly/45mTklZ

The #STEEL trial: Evaluating enzalutamide + ADT with salvage RT for high-risk recurrent #ProstateCancer. Edwin Posadas, MD Cedars-Sinai joins Zach Klaassen Georgia Cancer Center to discuss the complexities and aspirations of this trial > bit.ly/3V0Kd70

Navigating #nmCRPC treatment in the PSMA PET era. Neal Shore, MD, FACS CURC joins Zach Klaassen Georgia Cancer Center to discuss this evolving landscape and delve into the significant impact of PSMA PET scans on diagnosing and treating nmCRPC. #WatchNow > bit.ly/3UHqk38

Non-metastatic CRPC in the era of PSMA PET imaging: Challenges and opportunities. Aaron Berger, MD Associated Urological Specialists joins Zach Klaassen Georgia Cancer Center to discuss the evolving landscape of #nmCRPC. #WatchNow > bit.ly/3Q5qWhy

Coming soon! Sept 13-17th #ESMO24 is right around the corner! If you haven't already, #SignUp for summaries by clinicians delivered straight to your inbox, and #StayTuned for coverage throughout the conference > bit.ly/3Z1hUaZ ESMO - Eur. Oncology Zach Klaassen Rashid K. Sayyid Julian Chavarriaga

Updates in managing #NMIBC from the latest Amer. Urol. Assn. guidelines! Jeffrey Holzbeierlein and @urodocash discuss key changes, including variant histology mgmnt, biomarker use post-BCG treatment, and perioperative intravesical chemotherapy > bit.ly/3whJDIk Society of Urologic Oncology

I am delighted to share our manuscript evaluating Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) in pts with #Urothelialcancer treated with ICIs Thanks to our amazing team Petros Grivas Ali Khaki Rafee Talukder University of Washington Fred Hutchinson Cancer Center sciencedirect.com/science/articl… (1/7)

Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer out on The Lancet Oncology thelancet.com/journals/lanon… This multicentre retrospective study aimed to compare the prognostic value of PSMA-PET using the PROMISE (PPP) stage against

Characterization of targets for antibody-drug conjugates in advanced #UrothelialCarcinoma. #ExpertCommentary Dr. Bishoy M. Faltas WCM Englander Institute for Precision Medicine discusses work from Bahlinger et al. in #Histopathology > bit.ly/4cFeKxD

Real-world evidence informs clinical decision-making in metastatic castration-resistant #ProstateCancer. Alan H Bryce City of Hope joins Elena Castro in this discussion as part of an Independent Medical Education Initiative supported by Bayer | Pharmaceuticals > bit.ly/3uRqzzS

Pleased to share our recent European Urology manuscript on post treatment PSA declines and patient survival and long term outcomes after 177Lu-PSMA-617 therapy from the VISION trial! DCI Center for Prostate & Urologic Cancers Michael Morris Novartis Cancer Duke Cancer sciencedirect.com/science/articl…

Preclinical study evaluates enfortumab vedotin and sacituzumab govitecan with radiation for #BladderCancer. Kent Mouw Dana-Farber and Leslie Ballas Cedars-Sinai discuss preclinical effects of combining EV and sacituzumab govitecan with radiation > bit.ly/4cfLyNc

PSMA PET imaging metrics like tumor volume & PSMA expression can predict survival better than traditional clinical scores. Researchers aim to combine imaging & clinical data to enhance risk stratification. Learn more on UroToday.com: tinyurl.com/3tb4hvpx

The future state of race & ethnicity in #Urology: Urology workforce projection from 2021-2061. Efe Chantal Ghanney Simons and Ashley Appleton join Ruchika Talwar to discuss this important issue and the slow growth of underrepresented minorities in urology > bit.ly/3RvBI1u

#PROMISE Criteria: Enhanced survival prediction in #Prostate Cancer with PSMA PET. Wolfgang Fendler, MD Uni Duisburg-Essen @unidue.bsky.social joins Phillip Koo, MD Banner Health to discuss advancements in PSMA PET imaging and its prognostic capabilities. #WatchNow on UroToday > bit.ly/3zBOEwK

Urine tumor DNA-informed analysis of ctDNA in patients with muscle-invasive #BladderCancer. #ExpertCommentary Dr. Bishoy M. Faltas WCM Englander Institute for Precision Medicine discusses work by BinHumaid et al. > bit.ly/3WgFaQf #MIBC

AUA/SUFU #OveractiveBladder guidelines emphasize shared decision-making. Ariana L Smith Penn Urology joins Diane Newman to discuss the shift from a stepwise therapy approach to a patient-centered menu of treatment option > bit.ly/3L8Cmyw Amer. Urol. Assn. SUFU

Navigating #NMIBC risk stratification and treatment. Neal Shore CURC joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss the crucial role of the Amer. Urol. Assn. guidelines, developed with significant contributions from Dr. Kamat and other leaders in the field > bit.ly/4ab7He6

🎥 francesco soria and Ashish M. Kamat, MD, MBBS discuss validating the IBCG scoring system for IR #BladderCancer, showing significant differences in recurrence and progression rates, and suggesting tailored treatments, impacting practice and guidelines. #WatchNow > bit.ly/3yRu7o0